On Sept. 16, 2020, AXIM Biotechnologies announced that it had filed an Emergency Use Authorization (EUA) application with…
On Sept. 15, 2020, the Tufts Center for the Study of Drug Development reported that new anti-infective drugs…
On Sept. 15, 2020, Soligenix announced publication of nonclinical results characterizing filovirus protein antigens (including for Ebola and…
On Sept. 15, 2020,Tonix Pharmaceuticals announced that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001),…
On Sept. 15, 2020, the University of Texas Health Science Center at Houston (UTHealth) announced that a study…
On Sept. 14, 2020, the National Institutes of Health (NIH) announced that it had added funding for more…
On Sept. 14, 2020, Mateon Therapeutics announced that its global study based on its ARTI-19 protocol for Artemisinin…
On Sept. 14, 2020, Eli Lilly and Incyte announced initial data from the Adaptive COVID-19 Treatment Trial (ACTT-2)…
On Sept. 14, 2020, Pascal Biosciences and SoRSE Technology announced they had entered into a collaborative research agreement…
On Sept. 9, 2020, NanoString Technologies announced the formation of the GeoMx Translational Leadership Network (GTLN). The GTLN…
On Sept. 10, 2020, GlaxoSmithKline and Innoviva announced the U.S. Food and Drug Administration (FDA) had approved a…
On Sept. 8, 2020, the CEOs of AstraZeneca, BioNTech, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, and…
On Sept. 8, 2020, RedHill Biopharma announced that opaganib demonstrated potent inhibition of SARS-CoV-2, the virus that causes…
On Sept. 8, 2020, a new collaboration between the California Institute for Regenerative Medicine (CIRM) and the Chan…
On Sept. 7, 2020, research from the Children’s Medical Center Research Institute at UT Southwestern (CRI) determined how…
On Sept. 3, 2020, RedHill Biopharma announced the selection of opaganib, a proprietary, first-in-class, orally-administered, sphingosine kinase-2 (SK2)…
On Sept. 3, 2020, Humanigen announced the first case-control data of lenzilumab in severe COVID-19 demonstrated an 80%…
On Sept. 3, 2020, BioCryst Pharmaceuticals announced that the U.S. Department of Health and Human Services (HHS) had…
On Sept. 2, 2020, Mesoblast announced that it had received ethics approval to include Australian hospitals in the…
On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a…
On Sept. 2, 2020, UT Southwestern (UTSW) announced that it had performed the first HIV-positive-to-HIV-positive organ transplant in…
On Sept. 1, 2020, scientists at deCODE genetics in Iceland, a subsidiary of Amgen, published a study in…
On Sept. 1, 2020, City of Hope announced that it was investigating an innovative treatment for cancer patients…
On Sept. 1, 2020, Sanofi announced that the global Phase 3 trial investigating intravenously administered Kevzara (sarilumab) at…
On Aug. 31, 2020, Novavax announced it had reached an agreement in principle with the Government of Canada…
On Aug. 31, 2020, BioCryst Pharmaceuticals announced that the National Institute of Allergy and Infectious Diseases (NIAID) had…
On Aug. 27, 2020, Assembly Biosciences and Arbutus Biopharma announced that the companies have entered into a clinical…
On Aug. 27, 2020, RedHill Biopharma announced that its U.S. Phase 2 study with opaganib (Yeliva®, ABC294640) in…
On Aug. 27, 2020, Laurent Pharmaceuticals announced that it had received approval from the U.S. Food and Drug…
On Aug. 27, 2020, Myriad RBM announced ultrasensitive immunoassays for viral pneumonia Including COVID-19 from our CLIA-certified laboratory….